Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in
patients with Waldenstrӧm's macroglobulinemia (WM). The study will evaluate this combination
in two cohorts. Cohort A will comprise of ibrutinib naïve WM patients. Patients in this
cohort may be treatment naïve or relapsed but who remain ibrutinib naïve. Cohort B will
comprise of patients who are currently receiving ibrutinib but whose response to treatment
has plateaued. In this cohort, daratumumab will be added on to ibrutinib in an attempt to
deepen response.